Old Web
English
Sign In
Acemap
>
authorDetail
>
Ursula A. Matulonis
Ursula A. Matulonis
Broad Institute
Ovarian cancer
Cancer research
Biology
Serous fluid
Medicine
3
Papers
3
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Abstract A04: Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers
2018
Clinical Cancer Research
Anniina Farkkila
Bose S. Kochupurakkal
Brooke E. Howitt
Kyle C. Strickland
Dipanjan Chowdhury
Geoffrey I. Shapiro
Evisa Gjini
Scott J. Rodig
Ursula A. Matulonis
Panagiotis A. Konstantinopoulos
Alan D. D'Andrea
Show All
Source
Cite
Save
Citations (0)
Abstract AP19: SINGLE–CELL RNA–SEQUENCING OF PATIENT–DERIVED OVARIAN CANCER CELLS AND PATIENT–DERIVED XENOGRAFT MODELS
2017
Clinical Cancer Research
Benjamin Izar
Elizabeth H. Stover
Itay Tirosh
Asaf Rotem
Parin Shah
Chris Rodman
Sanjay Prakadan
Marc Wadsworth
Mei-Ju Su
Rachel Leeson
Sangeetha Palakurthi
Joyce Liu
Ursula A. Matulonis
Alex K. Shalek
Orit Rozenblatt-Rosen
Aviv Regev
Levi A. Garraway
Show All
Source
Cite
Save
Citations (3)
• Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting new classes of targeted agents for ovarian cancer treatment. • PARP inhibitors have demonstrated single-agent activity in BRCA-related ovarian cancer and sporadic high grade serous ovarian cancer. • Phase III PARP inhibitor studies have been launched for newly diagnosed germline BRCA cancers and platinum sensitive recurrent ovarian cancer.
2014
Joyce Liu
Panagiotis A. Konstantinopoulos
Ursula A. Matulonis
Show All
Source
Cite
Save
Citations (0)
1